Moore Capital Management LP purchased a new stake in Neurogene Inc. (NASDAQ:NGNE – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 141,636 shares of the company’s stock, valued at approximately $4,454,000.
Other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP acquired a new position in Neurogene during the 2nd quarter worth approximately $987,000. Seven Fleet Capital Management LP bought a new stake in shares of Neurogene in the 2nd quarter valued at about $694,000. Bank of America Corp DE bought a new stake in Neurogene in the second quarter valued at approximately $350,000. Trails Edge Capital Partners LP acquired a new stake in shares of Neurogene during the second quarter worth $22,483,133. Finally, ADAR1 Capital Management LLC acquired a new stake in Neurogene during the 2nd quarter worth about $245,000. Institutional investors and hedge funds own 52.37% of the company’s stock.
Insider Activity at Neurogene
In other Neurogene news, CFO Christine Mikail Cvijic sold 4,200 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total value of $151,746.00. Following the completion of the sale, the chief financial officer owned 84,040 shares of the company’s stock, valued at $3,036,365.20. This represents a 4.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 9,600 shares of company stock worth $339,932. 11.68% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on Neurogene
Neurogene Trading Down 0.9%
Neurogene stock opened at $36.24 on Tuesday. The firm has a market capitalization of $725.16 million, a PE ratio of -7.20 and a beta of 1.70. The firm’s 50 day simple moving average is $35.89 and its 200 day simple moving average is $28.51. Neurogene Inc. has a 1-year low of $15.93 and a 1-year high of $43.66.
Neurogene (NASDAQ:NGNE – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.42) by ($0.11). Research analysts forecast that Neurogene Inc. will post -5.62 earnings per share for the current year.
Neurogene Company Profile
Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.
Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.
Recommended Stories
- Five stocks we like better than Neurogene
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding NGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurogene Inc. (NASDAQ:NGNE – Free Report).
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.
